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Risk of Early Versus Later Rebleeding From
Dural Arteriovenous Fistulas With Cortical Venous
Drainage
Andrew J. Durnford, MA, MSc; Danyal Akarca , BMBS, MPhil; David Culliford , PhD; John Millar, BMBS;
Ridhima Guniganti, MD; Enrico Giordan , MD; Waleed Brinjikji , MD; Ching-Jen Chen , MD;
Isaac Josh Abecassis , MD; Michael Levitt , MD; Adam J. Polifka , MD; Colin P. Derdeyn , MD;
Edgar A. Samaniego , MD; Amanda Kwasnicki, MD; Ali Alaraj , MD; Adriaan R.E. Potgieser, MD, PhD; Stephanie Chen, MD;
Yoshiteru Tada , MD, PhD; Ryan Phelps , MD; Adib Abla , MD; Junichiro Satomi, MD, PhD; Robert M. Starke, MD, MSc;
J. Marc C. van Dijk, MD, PhD; Sepideh Amin-Hanjani , MD; Minako Hayakawa, MD; Bradley Gross , MD;
W. Christopher Fox , MD; Louis Kim , MD; Jason Sheehan , MD, PhD; Giuseppe Lanzino , MD;
Akash P. Kansagra , MD; Rose Du , MD; Rosalind Lai , MD; Gregory J. Zipfel , MD; Diederik O. Bulters , MB ChB;
on behalf of the CONDOR Investigators*
BACKGROUND: Cranial dural arteriovenous fistulas with cortical venous drainage are rare lesions that can present with
hemorrhage. A high rate of rebleeding in the early period following hemorrhage has been reported, but published long-term
rates are much lower. No study has examined how risk of rebleeding changes over time. Our objective was to quantify the
relative incidence of rebleeding in the early and later periods following hemorrhage.
Downloaded from http://ahajournals.org by on September 24, 2022

METHODS: Patients with dural arteriovenous fistula and cortical venous drainage presenting with hemorrhage were identified
from the multinational CONDOR (Consortium for Dural Fistula Outcomes Research) database. Natural history follow-up was
defined as time from hemorrhage to first treatment, rebleed, or last follow-up. Rebleeding in the first 2 weeks and first year
were compared using incidence rate ratio and difference.
RESULTS: Of 1077 patients, 250 met the inclusion criteria and had 95 cumulative person-years natural history follow-up. The
overall annualized rebleed rate was 7.3% (95% CI, 3.2–14.5). The incidence rate of rebleeding in the first 2 weeks was
0.0011 per person-day; an early rebleed risk of 1.6% in the first 14 days (95% CI, 0.3–5.1). For the remainder of the first
year, the incidence rate was 0.00015 per person-day; a rebleed rate of 5.3% (CI, 1.7–12.4) over 1 year. The incidence rate
ratio was 7.3 (95% CI, 1.4–37.7; P, 0.026).
CONCLUSIONS: The risk of rebleeding of a dural arteriovenous fistula with cortical venous drainage presenting with hemorrhage
is increased in the first 2 weeks justifying early treatment. However, the magnitude of this increase may be considerably lower
than previously thought. Treatment within 5 days was associated with a low rate of rebleeding and appears an appropriate
timeframe.
GRAPHIC ABSTRACT: A graphic abstract is available for this article.
Key Words: drainage ◼ fistula ◼ hemorrhage ◼ incidence ◼ natural history
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ranial dural arteriovenous fistulas (dAVFs) are abnormal anastomoses within the dura mater. They can be
classified based on their venous drainage into those
with or without cortical venous drainage (CVD). dAVF
without CVD rarely causes intracranial bleeding, while
those with CVD may cause hemorrhage.1–3
The risk of bleeding of dAVF with CVD has been
studied in 5 cohort studies.4–8 Each study reported either
overall annualized average hemorrhage rates or compared groups using Kaplan-Meier analyses. None have
considered whether the rate of hemorrhage changes
over time following presentation.
Several studies have reported rates of rebleeding following hemorrhagic presentation. One focused on early
rebleeding reported that 35% of dAVF with CVD presenting with hemorrhage suffered a rebleed within the
first 2 weeks.9 Five other studies have reported annualized rebleed rates varying from 7.4%5 to 46%,10 although
none have reported if this risk changes over time.
The rate of early rebleeding has important clinical ramifications for when to treat and whether to treat. A very high
rate of rebleeding may mandate immediate treatment,
potentially with less experienced teams. Lower rebleed
rates would support early but planned treatment and more
subspecialization in the treatment of rare lesions (crude
detection rate 0.16/100 000 adults per year).11 If there
were no additional early rebleed risk at all, with annualized
risks quoted at 7.4% per annum, some unstable patients
may be more appropriate for delayed treatment and some
very frail or elderly patients no treatment at all.
We therefore aimed to study how the rate of hemorrhage changes over time following a hemorrhagic
presentation of cranial dAVF with CVD using the CONDOR (Consortium for Dural Fistula Outcomes Research)
database.

METHODS
Data Availability
The data that support the findings of this study can be requested
from the CONDOR registry central repository (Dr Zipfel, zipfelg@wustl.edu); data requests are subject to approval of the
CONDOR consortium.

Patients
CONDOR comprises 14 centers in the United States, the
United Kingdom, the Netherlands and Japan who have pooled
Stroke. 2022;53:2340–2345. DOI: 10.1161/STROKEAHA.121.036450

their data from 1077 dAVF patients seen between 1990 and
2017. The contributing date ranges varied between centers.
The formation and methodology of the CONDOR database
has been described in detail elsewhere.12 All centers had institutional or ethics committee approval with waiver of written
informed consent. Data of patients with dAVF and CVD were
extracted. The TRIPOD guideline for reporting of prediction
model development and validation was used and a checklist is
presented in Table S1.

Natural History Periods
The natural history period was defined as the time period from
presentation with a hemorrhage related to the dAVF to the time
of first treatment, rebleed, dAVF regression, or last follow-up.
First treatment was considered as any attempt at treatment
irrespective of whether it resulted in complete or partial cure of
the dAVF. In cases of multiple hemorrhages during the natural
history period, the number of hemorrhages was recorded, but
patients were censored at time of first rebleed. The reasons
some patients did not undergo treatment varied but included
patient refusal poor clinical condition and comorbidities preventing treatment.

Hemorrhage
All hemorrhages were confirmed radiologically on computed
tomography (CT) or magnetic resonance imaging, or cerebrospinal fluid analysis from lumbar puncture. A hemorrhage was
defined as dAVF related if it met any of the following criteria: (1) blood was located in the vicinity of the fistula’s venous
outflow; (2) angiography showed contrast extravasation from
the fistula; or (3) clinical notes indicated the dAVF as the likely
cause of bleeding and no other cause more likely. This relationship was adjudicated by the investigators in local participating
centers and all dAVF-related hemorrhages included if judged
as certain or probable. The primary outcome was incidence of
dAVF-related rehemorrhage on follow-up during the natural
history period. Hemorrhages were further classified as intracerebral, subarachnoid, or intraventricular.

Statistics
The incidence rate of further hemorrhage per person-time in
the defined follow-up period was calculated, with 95% CIs
using the Byar method and P by the Mid-P exact test, for both
the first 2 weeks and the remainder of the subsequent year.
Baseline demographics and characteristics of the patients
contributing to the early and late cohorts were compared with
assess for confounding factors using χ2 and t-tests where
appropriate. Incidence rates were compared by incidence rate
ratio and difference with 95% CIs using the Byar method.
There were no missing data, so no imputation was required.

RESULTS
Of 1077 patients with dAVF, 692 had CVD, while the
remaining either had no CVD (n=373) or missing data
(n=12). Of those with CVD, 37% (n=253) presented
with a dAVF-related hemorrhage. There were a further 7
patients who suffered dAVF-related hemorrhage before
July 2022   2341
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treatment but after initial nonhemorrhagic presentation
and had subsequent natural history period data; therefore, in total, 260 patients had CVD and hemorrhagic
presentation. Ten patients were excluded for missing
follow-up data. Overall, 250 patients formed the analysis cohort comprising 95 years of cumulative personyears natural history follow-up (Figure S1). Median time
to censorship was 5 days (interquartile range 40 days);
242 patients were censored because of treatment, one
because of spontaneous obliteration of their fistula and
7 patients experienced a further dAVF-related hemorrhage (Figure), approximating to an annualized rebleed
rate of 7.3% (95% CI, 3.2–14.5). One patient suffered
2 dAVF-related rehemorrhages. There were no deaths
following rebleeding, and all patients underwent subsequent treatment. Of those that rebled, fistula location
was tentorial in 4, transverse sinus in 2, and convexity in
1. Of those that rebled, 43% were female, median age
was 56 years (range, 0–85), and 57% had venous ectasia. Their presenting bleed was intracerebral in 4 cases,
combined intracerebral and subarachnoid in 2 cases, and
subarachnoid in 1 case.
The patients contributing to the early and late
rebleeding risk are summarized in Table 1. The incidence rate in the first 2 weeks following a previous
hemorrhage was 0.001106 per person-day of followup (95% CI, 0.0001854–0.003653), approximating
to an early rebleed risk of 1.6% (95% CI, 0.3–5.1) in
the first 2 weeks. After 2 weeks, the incidence rate of
dAVF-related rehemorrhage was 0.000151 (95% CI,
0.0000487–0.000353) per person-day of follow-up
until censorship, approximating to a late rebleed risk of

Time-Course of Dural Fistula Rebleed Risk

5.3% (CI, 1.7–12.4) for the remainder of the first year.
The incidence rate ratio for rebleeding before and after
2 weeks was 7.3 (95% CI, 1.4–37.7; P 0.026) and the
incidence rate difference 9.5 (95% CI, −5.8 to s24.9).

DISCUSSION
Previous data suggested that the rebleeding risk in the
first 2 weeks after hemorrhage was 35%.9 The current
study challenges this estimate. Although we demonstrate
for the first time that there is an early period of increased
bleeding risk, its magnitude is significantly smaller than
previously thought. Using the largest available database
of dAVF with CVD, the incidence of bleeding was found
to be 1.6% in the first 2 weeks, with an upper 95% confidence limit of 5.1%.
Rebleeding following dAVF hemorrhage is associated
with a significant risk of morbidity or mortality.4,13 The
long-term incidence of rebleeding in the current series
is in agreement with similar published natural history
cohorts.5 It therefore remains for the vast majority that
early treatment is mandated. The lower than previously
reported magnitude of the early risk raises questions,
however, as to what constitutes early treatment. With a
daily risk of 0.11% per day in the first 2 weeks, timing
of treatment must carefully balance the best clinical outcome with an expeditious one. That balance of risk will
vary depending on local pathways and resources. Transfer to more experienced institutions or time for further
optimization before anesthesia may be warranted. In our
series, a median time to treatment of 5 days was associated with a very low rate of rebleeding and would seem

Figure. Kaplan-Meier curve showing the survival of patients with cortical venous drainage (CVD).
A, All patients with CVD from time of first fistula related hemorrhage to rebleed for the first year of natural history follow-up and (B) for the first
30 d only (represented by boxed area in A). Patients were censored at first treatment or last follow-up if no treatment was received. Time in
days. The red shaded areas represent the 95% CIs for patient survival without dural arteriovenous fistula (dAVF)-related rehemorrhage. Thirteen
patients had follow-up beyond 1 y, which is not depicted.
2342   July 2022
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Measure

Cohort with day
1- to 2-wk data

Cohort with post
2-wk data

Number

n=250

n=90

Mean age

59 y

57 y

0.179

Sex

70% male

69% male

0.422

Borden 2

14%

11%

0.244

Borden 3

86%

89%

0.244

Type IIa+b

7.2%

3.3%

0.096

Type IIb

5.6%

7.7%

0.231

Type III

37.6%

44.4%

0.127

Type IV

47.2%

40.0%

0.120

Type V

0.8%

1.1%

0.393

Unknown

1.6%

4.4%

0.063

Venous ectasia

54.8%

45.6%

0.066

Tentorial location

29.2%

22.2%

0.102

Intraparenchymal

73.5%

70.0%

0.524

Subarachnoid

43.9%

38.6%

0.391

Intraventricular

29.5%

17.2%

0.026

P value

Borden grade

Cognard grade

Location of hemorrhage

Downloaded from http://ahajournals.org by on September 24, 2022

While the primary analysis used 14 d for comparison to the existing literature, as a sensitivity analysis, IRRs and IRDs were calculated for alternative time
periods. These were selected as 48 h, representing the time of greatest risk of
rupture for ruptured aneurysms, 5 d representing the median time to treatment
in this cohort, and 6 mo representing the period of increased risk of bleeding of
an aneurysm after rupture. These results are displayed in Table 2. IRD indicates
incidence rate difference; and IRR, incidence rate ratio.

acceptable, although we would generally advocate the
principle that earlier is better, up to the point where the
quality of the procedure may be compromised.
The lower than previously reported early rebleed rate
means that in a minority of patients who are very frail or
medically unstable, the risk of rebleeding may be smaller
than the risks of treatment. However, this is likely to be
a very small group of patients in whom anesthetic risks
are exceedingly high. It also raises the question whether
patients presenting in coma should be treated acutely or
upon showing signs of recovery. We have not presented
any data on recovery from hemorrhage that would be
needed to base any recommendations on. However, our
in our experience by 5 days, imaging and clinical findings are sufficiently clear whether patients are likely to
make a meaningful recovery or not to be able to decide
whether to treat or not.

Comparison to the Literature—Early Rebleeding
While risk of early rebleed was considerably smaller than
previously reported, factors including sample size, selection bias, or different definitions of natural history and
rebleeding may account for this.
Stroke. 2022;53:2340–2345. DOI: 10.1161/STROKEAHA.121.036450

The Duffau series was small (n=20), and both
series were open to selection bias, primarily from loss
of patients to treatment. This bias may be greater
in the current series of patients, which were treated
more recently. However, the most accepted predictor
of repeat hemorrhage of dAVF with CVD is venous
ectasia.7 In this series, 55% of cases and ≈40% in
the Duffau series had venous ectasia, and this does
not seem to explain the discrepancy in rebleed risk.
All patients in the Duffau series were Cognard type
III or IV fistula and while event rates did not permit
subgroup analysis, ≈85% of our cohort was type III
or IV of which 4 rebled (of 7). The only other putative
predictor of rebleeding is tentorial location14 but was
similar in both series.
The definition of rebleeding utilized in the present
study is also different. In the prior study, only 4 of 20
cases (20%) had CT confirmed rebleeding, in others, it
included the presence of differing aged blood at surgery
and increased mass effect on serial angiographic imaging. In our study, all rebleeding was confirmed on imaging.
Not all dAVF in the Duffau series had an angiographic
diagnosis. Notably, one case of recurrent acute subdural hemorrhage after previous subdural evacuation was
attributed to dAVF rebleeding with no other objective
evidence. All cases in our dataset had an angiographic
diagnosis.

Comparison to the Literature—Longer Term
Rebleed
The overall annualized rate of rebleeding was 7.3% which
is in agreement with published rates. Soderman et al5
reported an annualized rate of 7.4% in one of the few
comparable datasets not included in the CONDOR. Other
reports are generally limited by their small sample size
and short follow-up, which are prone to overestimating
annualized rebleeding risk. For example, a recent study
across 3 cohorts with 169 dAVFs with CVD reported an
annualized rebleed rate of 46%; however, mean followup was 0.3 years.8 Some studies included partially treated
lesions and nonhemorrhagic presentations.4 Studies of
patients specifically presenting with hemorrhage have
not reported rebleeding incidence rates.14,15

Strengths and Limitations
Both a strength and limitation of this study is its sample size. It is the largest analysis of patients with dAVF
hemorrhage, and the first specifically reporting both
early and late rebleeding rates. Despite this, the number of rebleeding events is low, limiting the degree of
applicable analysis. However, given the known natural history, it is unlikely further significant amounts
of natural history data will be collected in the future,
and while some published series are not included in
July 2022   2343
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Table 2. Secondary Analysis of Incidence Rates and Risk
Time period

<2 d

>2 d

<5 d

>5 d

<14 d

>14 d

<30 d

>30 d

<6 mo

>6 mo

Number
censored

83

167

120

130

160

90

182

68

221

29

Cum FU, d

433

34 421

882

33 972

1837

33 017

3053

31 801

9371

25 483

Rebleeds

1

6

2

5

2

5

4

3

5

2

Incidence
per personday (CI
95%)

0.0023096
(0.000030–
0.01285)

0.000174
(0.000064–
0.000379)

0.002268
(0.000255–
0.008187)

0.0001454
(0.000047–
0.000339)

0.001106
(0.0001854–
0.003653)

0.000151
(0.0000487–
0.000353)

0.00131
(0.000353–
0.03354)

0.000094
(0.000024–
0.000256)

0.000534
(0.000172–
0.00125)

0.000078
(0.000013–
0.000260

Incidence
(as %)

0.46%
(0.6%–
2.6%)

6.33%
(2.3%–
13.7%)

1.15%
(0.1%–
4.1%)

5.3%
(1.7%–
12.2%)

1.6%
(0.3%–5.1%)

5.1% (1.7%–
12.4%)

3.93%
(1.1%–
10.1%)

3.16%
(0.8%–
8.6%)

9.74%
(3.1%–
22.7%)

1.43%
(0.24%–
4.7%)

IRR

13.4

…

15.7

…

7.3

…

14.8

…

8.2

…

IRR 95% CI

(1.6–111.1)

…

(3.1–80.9)

…

(1.4–37.7)

…

(3.3–66.0)

…

(1.6–42.3)

…

We present before and after 2 d, 5 d, 14 d, 30 d, and 6-mo periods. FU indicates follow-up; and IRR, incidence rate ratio.
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this analysis, these groups declined participation in
the consortium. We therefore think this represents
the best dataset likely to become available to address
this issue. Other strengths are it is a multicenter study
with well-defined methodology, and definitions developed by a consortium of experts and subject to careful quality control.
The main limitations are its retrospective nature
and risk of selection bias. Ultra-early rebleeding
either before admission to hospital, or before a scan
is obtained may be undetected and lead to underestimation of the absolute early rebleed risk as has been
observed in other conditions.16 In addition, the study
included only tertiary referral centers and will not have
included some patients admitted to secondary care
and not referred either because they were too unwell
to proceed with angiography and treatment, or due
to an early rebleed. This may have led to underestimates of absolute rebleed rates, although in terms of
generalizability to patients admitted to neurosciences
centers, the presented data would be representative.
Within this population, the median time to treatment
was 5 days, and approximately one-third were treated
within 2 days and thus early censorship is a limitation.
In view that only 29 patients were available beyond 6
months means the late risks are particularly vulnerable to error. Clinicians could be selecting higher risk
patients for earlier treatment. This could have led to an
underestimate of the rebleeding risk.

CONCLUSIONS
We demonstrate that the risk of rebleeding of a dAVF
with CVD presenting with hemorrhage is significantly
increased in the first 2 weeks. However, the magnitude
of this increase appears lower than previously thought.
The absolute incidence of a second bleeding episode in
the first 2 weeks of 1.6%, and the long-term annualized
risk of 7.3% means that treatment remains mandated in
the vast majority of cases. In this series treatment within
2344   July 2022

5 days resulted in a low rate of rebleeding and appears
to be an appropriate timeframe.
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